Clinical Trial Update: A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus [Phase 3]

View source ↗

Summary

Phase 3 trial comparing LY2963016 to Lantus in adult Chinese participants with Type 1 diabetes has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• LY2963016 (insulin glargine)
• Lantus (insulin glargine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Type 1 Diabetes | Phase 3 | Status: COMPLETED | Results posted: 2021-03-29